Container Closure Integrity
The ability of a pharmaceutical container and its closure system to maintain a sterile barrier against microbial contamination throughout the product's shelf life. For peptide drugs, container closure integrity testing ensures that vials, syringes, and cartridges protect the product from environmental degradation.
Technical Context
CCI testing ensures the container-closure system maintains a microbial and physical barrier throughout shelf life. Methods: deterministic (providing quantitative measurement — helium leak testing, high-voltage leak detection, headspace analysis, vacuum decay) and probabilistic (based on microbial challenge — dye immersion/ingress, microbial immersion). USP <1207> provides guidance. For peptide drug products, CCI is critical because: parenteral products must remain sterile, peptides can be degraded by oxygen (Met oxidation, Trp degradation) requiring inert headspace, and moisture ingress can destabilise lyophilised products. Vial systems: Type I borosilicate glass vials with bromobutyl rubber stoppers and aluminium flip-off seals. Pre-filled syringe systems: glass barrel, elastomeric plunger stopper, rigid needle shield. Pen cartridge systems: glass barrel, bromobutyl rubber disc seal, aluminium crimp. Each system requires CCI validation specific to the product and process.